Taylor & Francis joins Open Pharma to boost research transparency in pharma

Taylor & Francis has officially joined Open Pharma as a Supporter. The publisher will now have privileged access to discussions and a role in shaping the project’s direction. Open Pharma focuses on making pharmaceutical industry-funded research more transparent and accessible. Open Pharma and Taylor & Francis recently announced the new partnership. The initiative already includes major companies like AstraZeneca, Pfizer, and Roche, as well as other publishers and medical communications firms.

Taylor & Francis is a leading scholarly publisher with a strong commitment to open research. Elizabeth Knowles, its Global Portfolio Director for Medicine, has publicly backed Open Pharma’s efforts to advance open science. In 2021, Open Pharma published recommendations for plain language summaries in Taylor & Francis’s journal Current Medical Research and Opinion. As a Supporter, Taylor & Francis will contribute to Open Pharma’s mission. The collaboration aims to improve the transparency and discoverability of industry-funded research. This partnership strengthens the initiative’s growing network across publishing and pharmaceutical sectors.